Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026

globenewswire.com
NVCT The article announces Nuvectis Pharma's upcoming Q3 2026 financial results and conference call. It provides details on the call, the company's focus on biopharmaceuticals for complement-related conditions and oncology, and its pipeline candidates. The sentiment is neutral as it's a factual announcement of an earnings report.

Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026 Fort Lee, NJ, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that it will host a conference call and webcast on Wednesday, November 4, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.

Conference Call and Webcast Information:

Date: 8:00 AM ET, Wednesday, November 4, 2026

Participant Dial-In (U.S.): 1-877-407-0752

Participant Dial-In (International): 1-201-389-0912

Conference ID: 13763643

Webcast Access: Please click here

The live and archived webcast can also be accessed by visiting the Nuvectis Pharma website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days following the presentation.

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP200 and NXP900, in development for the treatment of advanced cancers.

The company’s lead drug candidate is NXP100 (ciprocopan), a once-a-day Factor B inhibitor, with best-in-class potential, recently approved in China for the treatment of PNH patients previously untreated with complement inhibitors.

NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, with best-in-class potential.

NXP900 is an oral, small molecule inhibitor of the SRC family kinases, including SRC and YES1.

Company Contact:

Ron Bentsur

Chairman, Chief Executive Officer and President

rbentsur@nuvectis.com

Media Relations Contact:

Kevin Gardner

LifeSci Advisors kgardner@lifesciadvisors.com